This score clearly outperformed methods based on the clinical significance of single biomarkers (such as AFP, AFP-L3, or DCP used separately) for early HCC detection in a large cohort of white patients with chronic hepatitis B or C. Moreover, GALAD proved to have good accuracy in identifying HCC patients, regardless of tumor burden, extent of concomitant liver disease, or baseline viral load [242]. The gene discussed is AFP; the disease is chronic hepatitis B virus infection.